Raleigh, NC – According to filings with the U.S. Securities and Exchange Commission, Innovate Biopharmaceuticals is raising $2,750,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Christopher Prior played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Innovate Biopharmaceuticals

Innovate is a publicly traded clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn’s, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.

To learn more about Innovate Biopharmaceuticals, visit http://www.innovatebiopharma.com/

Contact:
Christopher Prior, Chief Executive Officer
919-275-1933
cprior@innovatebiopharma.com
https://www.linkedin.com/in/chris-prior-56515314b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved